You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Roche’s Tecentriq/Avastin combo improves survival in liver cancer

Roche is planning to present updated data confirming that its immunotherapy combination, consisting of Tecentriq (atezolizumab) and Avastin (bevacizumab), improves overall survival (OS) in patients with a type of liver cancer.